A5087479854- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Circular RNAs in diseases
- Chronic Lymphocytic Leukemia Research
- RNA Interference and Gene Delivery
- Genomics and Chromatin Dynamics
- RNA modifications and cancer
- Telomeres, Telomerase, and Senescence
- Epigenetics and DNA Methylation
- Oral Health Pathology and Treatment
- Seaweed-derived Bioactive Compounds
- Cancer Cells and Metastasis
- Ion channel regulation and function
- Head and Neck Cancer Studies
- RNA Research and Splicing
- Synthesis of Organic Compounds
- Advanced biosensing and bioanalysis techniques
- Inhalation and Respiratory Drug Delivery
- Carbohydrate Chemistry and Synthesis
- Cancer Immunotherapy and Biomarkers
Greater Poland Cancer Center
2016-2022
Poznan University of Medical Sciences
2016-2022
Centrum Onkologii
2016-2019
Head and neck cancer is characterized by malignant tumors arising from the epithelium covering upper aerodigestive tract, majority of these epithelial malignancies are squamous cell carcinomas (SCCs) oral cavity (OSCCs). The aim current work was to identify miRNAs regulated in OSCC cancerous tissue when compared a healthy adjacent verify presence same circulation patients. For that serum samples biopsies tumor tissues were collected five patients diagnosed with cavity, RNA extracted...
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide. These tumors originate from epithelial cells of upper aerodigestive tract. HNSCC in different regions can have significantly molecular characteristics. While many microRNAs (miRNAs) been found to be involved regulation carcinogenesis pathogenesis HNSCC, new related miRNAs are still being discovered. The aim this study was explore potential miRNA biomarkers that used diagnose prognose survival patients....
Squamous cell carcinoma of the head and neck (HNSCC) is sixth leading cause cancer worldwide, representing over half a million incidents every year. Cancer cells, including HNSCC, are characterized by increased telomerase activity. This enzymatic complex active in ~90% all types responsible for lengthening telomeres. Highly recurrent point mutations human reverse transcriptase (hTERT) promoter have recently been reported number neoplasms. The aim present study was to analyze prevalence hTERT...
Abstract The aim of the study was to analyze effect hTERT gene knockdown in HNSCC cells by using novel vitro models head and neck cancer (HNSCC), as well improving its personalized therapy. To obtain most efficient siRNA, shRNA-bearing lentiviral vectors were used. efficiency silencing verified with qPCR, Western blot, immunofluorescence staining. Subsequently, type cell death DNA repair mechanism induction after assessed same methods, followed flow cytometry. a combined treatment on...
Cancer cells, including head and neck cancer cell carcinoma (HNSCC), are characterized by an increased telomerase activity. This enzymatic complex is active in approximately 80–90% of all malignancies, regulated various factors, methylation status hTERT gene promoter. pattern has been thoroughly studied so far. It was proved that aberrantly methylated tumor tissue versus healthy counterparts. However, such effect not yet investigated PBLs (peripheral blood leukocytes) patients. The aim this...
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer worldwide. The treatment choice in case head surgery, followed by chemo- or/and radiotherapy. A potentially effective instrument to improve outcome numerous diseases, including viral infections, diabetes cancer, RNA interference (RNAi). It has been demonstrated that small interfering microRNA molecules are strongly involved regulation various different pathological processes development. RNAi become a valuable...
Previous studies have shown that the chloride intracellular channel 1 (CLIC1) protein is overexpressed in oral squamous cell carcinoma (OSCC) and nasopharyngeal carcinoma. Patients with these diseases had significantly higher CLIC1 plasma levels than healthy controls.To determine concentration of patients OSCC laryngeal (LSCC).We collected blood samples from diagnosed (n = 13) LSCC 7), as well controls 8). The were centrifuged to obtain stored at -80°C. was determined using enzyme-linked...
Abstract Human induced pluripotent stem cells (hiPSCs) can be differentiated into chondrocyte-like cells. However, implantation of these is not without risk given that those transplanted may one day undergo ionizing radiation (IR) in patients who develop cancer. We aimed to evaluate the effect IR on from hiPSCs by determining their gene and microRNA expression profile proteomic analysis. Chondrocyte-like were placed a purpose-designed phantom model laryngeal cancer irradiated with 1, 2, or 3...
Rak płaskonabłonkowy rejonu głowy i szyi (HNSCC, ang. Head and Neck Squamous Cell Carcinoma) jest szóstym najczęściej występującym nowotworem na świecie. Leczenie tego typu nowotworów polega głównie stosowaniu metod chirurgicznych uzupełnionych pooperacyjną chemio- i/lub radioterapią. Prowadzone są też badania nad zastosowaniem terapii genowej poprzez wykorzystanie zjawiska interferencji RNA (RNAi, interference). RNAi efektywnym narzędziem w wielu chorób, takich jak zakażenia wirusowe,...
Nowotwory nadal stanowią jedną z głównych przyczyn śmiertelności w populacji światowej, a długotrwałe ich leczenie jest trudne i wysoce problematyczne, pomimo znacznego pogłębienia wiedzy zakresu biologii. Obecnie wykorzystywane metody terapeutyczne cechują się wysoką toksycznością, tym samym często udaremniając skuteczne wyleczenie pogarszając jakość życia chorych. Z tego względu wzrasta zainteresowane środkami, które mogłyby wzmocnić skuteczność konwencjonalnej terapii lub ograniczyć...
Płaskonabłonkowy rak głowy i szyi (HNSCC, ang. Head and Neck Squamous Cell Carcinoma) to nowotwór wywodzący się z komórek płaskonabłonkowych błon śluzowych jamy ustnej, nosa lub gardła. Pomimo znacznych postępów konwencjonalnych metod leczenia, 5-letni wskaźnik przeżycia bez progresji u pacjentów miejscowo zaawansowanym HNSCC HPV(-) nadal nie przekracza 50%. Niskie wskaźniki w połączeniu wysoką toksycznością stosowanych terapii, podkreślają konieczność wprowadzenia nowych strategii...